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Haematology counterAbstract Glanzmann thrombasthenia (GT) and Bernard–Soulier syndrome (BSS) are hereditary
autosomal recessive disorders of platelet functions. These two congenital thrombopathies are very
rare. This rarity might be due to the misdiagnosis of the disease and the lack of reliable screening
methods. Usually, the deﬁnitive diagnosis of these congenital defects relies on aggregometric, ﬂow
cytometric and molecular assays. Unfortunately, these expensive diagnostic tools are not always
available in routine laboratories, especially in developing countries, leading to misdiagnosis and
underestimation of the prevalence of these defects. In this paper, the authors suggest a simple
and accessible screening method for detection of congenital thrombopathies using only a haematol-
ogy counter and some reagents.
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Hereditary defects of platelet functions (thrombopathy) are
rarer than diseases related to defects in the soluble clotting
factors [1]. Glanzmann thrombasthenia (GT) and Bernard–
Soulier syndrome (BSS) are the best characterised inheritednakhla, Canastel, 31132 Oran, Al
. Brahimi).
niversity of Medical Sciences. Pub
h/
/j.jmhi.2012.09.003disorders of platelets [2]. A number of other congenital
thrombopathies are exceptional and difﬁcult to diagnose [3].
GT is the most common defect [3]. It is an autosomal reces-
sive inherited qualitative platelet disorder characterised by
quantitative or qualitative disorder of the platelet glycoprotein
GPIIb or GPIIIa [4]. The GPIIb–IIIa complex is the ﬁbrinogen
receptor, which plays a very important role in platelet aggrega-geria.
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tribution had been reported by several authors [5–7]. The rea-
son for this uneven distribution is the frequent occurrence of
intermarriage in some regions, allowing expression of autoso-
mal recessive traits and suggesting a rare occurrence of asymp-
tomatic heterozygous subjects [5].
BSS is also an autosomal recessive disorder. The underlying
defect is a deﬁciency or a dysfunction of the glycoprotein
GPIb-V-IX complex, a platelet-restricted multisubunit recep-
tor, required for normal primary haemostasis [8,9]. BSS is a
much less common bleeding disorder than GT; only about
100 cases have been reported in the literature [8,9]. Prevalence
has been estimated at less than 1/1 000 000 cases/Hab/year but
is probably higher due to misdiagnosis and underreporting [9].
Therefore, although BSS and GT are typically rare disor-
ders, they can be almost as frequent as haemophilia and von
Willebrand disease in regions where consanguinity is common
and an accepted custom.
The deﬁnitive diagnosis of these congenital defects relies on
aggregometric, ﬂow cytometric and molecular assays. Unfor-
tunately, these expensive diagnostic tools are not always avail-
able in routine laboratories, especially in developing countries,
leading to misdiagnosis and underestimation of the prevalence
of these defects.
In this paper, the authors suggest a simple and more acces-
sible screening method for detection of congenital thrombopa-
thies using only an impedance haematology counter and some
reagents.
Concept
It is well known that the platelet count is underestimated, by
an automated cell counter, each time platelet aggregates are
present in the sample tube [10–12].
The adjunction of a platelet agonist to a normal sample
tube will lead to a formation of aggregates and therefore to
a drop of the platelet count.
In the case of a hereditary platelet dysfunction, upon the
adjunction of a platelet agonist, aggregates cannot be formed,
and then the platelet count will remain the same.
Nowadays, haematology cell counters are available in the
majority of routine laboratories and platelet agonists such as
adenosine diphosphate (ADP), thrombin and restocintin can
be easily and cheaply purchased. For these reasons, the pro-
posed concept can contribute to develop a more accessible
screening technique for these hereditary platelet dysfunctions.
As impedance counters are the most widespread systems, this
method can be generalised in most laboratories.
Evaluation of the method
The blood of normal subjects should be used for the standardi-
sation of the method and the deﬁnition of the normal ranges.
Blood samples must be drawn into evacuated tubes containing
0.1 M buffered citrate (ratio citrate/blood = 1/9). Ethylene
diamine tetraacetic acid (EDTA) is not suitable for use in
aggregation testing as it does not leave sufﬁcient Ca2+ avail-
able for aggregation to occur [12]. All blood samples must
be processed within 2 h of collection in order to prevent the
changes in pH [13].Platelet count must be determined before (baseline count)
and after (post-activation count) the addition of the agonist.
The percentage of platelet aggregation can be calculated using
the following formula:
PercentageofAggregation
¼ðBaselinePlateletCountÞðPost-ActivationPlateletCountÞ
BaselinePlateletCount
100
It is well known that impedance instruments are the most
used in routine laboratories. For this purpose, a brief reminder
of how an impedance haematology counter works (Coulter
Principle) is necessary: On most haematology analysers, a
blood sample is diluted in saline, a good conductor of electrical
current, and the cells are pulled through an aperture by creat-
ing a vacuum [14]. Electrical resistance or impedance occurs as
the cells pass through the aperture causing a change in voltage.
This change in voltage generates a pulse. The number of pulses
is proportional to the number of cells counted. The size of the
voltage pulse is also directly proportional to the volume or the
size of the cell. Then, all cells can thus be both counted and
sized from the electrical impulses that they generate [10].
Depending on the model of instrument, platelets and red
cells may be separated from each other by a ﬁxed threshold,
for example, at 20 ﬂ, or by a moving threshold or the data
from counts between two thresholds, for example, 2 and
20 ﬂ. Hence, cells bigger than 20 ﬂ are not recognised as plate-
lets but as red cells [10].
In order to standardise this technique, the amount of whole
blood and the dose of the agonist must be determined with pre-
cision. As platelets aggregate in response to an activating stim-
ulus, they stick together to form ever-increasing sizes of
aggregates until no single platelets remain [15]. Thus, as the de-
gree of aggregation in a sample increases, the platelet count
falls.
An aggregate containing many platelets will be so big so
that it will not be detected by an impedance counter with typ-
ical limit settings.
However, an impedance counter can detect microaggre-
gates that contain two (or even three or four) platelets
(although it will count this as one particle) [15].
Therefore, if all the platelets in a sample formed aggregates
of two platelets per aggregate, which were measured by the
counter, then the platelet count would be theoretically ex-
pected to fall by 50% and the mean platelet volume (MPV) will
go up to 200%.
The aim, in the standardisation process, is to determine the
amount of normal blood and the agonist dose that leads to
platelet counts fall of 33–50% and an MVP rise of 200–
300%, that is, aggregates containing two to three platelets.
Low levels of activation of platelets frequently result in
transient and reversible aggregation responses. The ﬁnal plate-
let count then depends on the time at which the sample is taken
after addition of the agonist [15]. It is therefore essential to
specify this time. Perhaps it might be more interesting to draw
a curve, ‘time’ versus ‘percentage of aggregation’, in order to
emphasis the kinetic of the process, that is, aggregation and
disaggregation.
To sum up, in order to standardise this technique, three
parameters must be determined: the amount of whole blood
to be tested, the agonist dose added to blood and ﬁnally the
timing of platelet count after agonist addition.
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known GT and BSS patients. The results must be compared to
normal controls.
As it has been mentioned above, there are several models of
impedance automated counters; therefore the quality control
and the calibration of the instrument must be preformed
according to the manufacturer’s instructions. It is well known
that blood smears have an increasingly important role in the
quality control of the platelet count [16]; besides, they repre-
sent a reliable tool for detecting platelet aggregates after the
addition of the agonist.
Discussion
GT and BSS are hereditary autosomal recessive disorders of
platelet functions. The deﬁnitive diagnosis relies essentially
on aggregometric and ﬂow cytometric assays. According to
the literature, these two congenital thrombopathies are very
rare [5,8,9]. This rarity might be due to the misdiagnosis of
the disease and the lack of reliable screening methods.
In this paper, the authors propose a simple and accessible
screening method for these disorders using a routine auto-
mated blood cell counter and some platelet agonist such as
ADP, ristocetin, thrombin, epinephrine, collagen and arachi-
donic acid. Even if this method is simple and intuitive, it has
never been used for screening of congenital thrombopathies.
Some reasons come to mind:
First, when platelets aggregate in response to an activating
stimulus, they stick together to form ever-increasing sizes of
aggregates (microthrombi); this might lead to clogging and
damaging the instrument. In a previous article, we described
and validated a platelet counting technique from blood smears
on the basis of platelet/red cell ratio [16]. This latter method
can be used as an alternative to automated counters. Besides,
blood smears are suitable tools for detecting platelet
aggregates [11].
Second, platelets must come into contact with each other to
be able to aggregate (the propinquity effect) [13]. If agonists
are added to no stirred platelets, they will become activated
but aggregation will not be sufﬁcient to induce a platelet count
drop. Some cheap semi-automated coagulometers can be used
for stirring the sample even if they are not dedicated to this
purpose.
Third, BSS are characterised by the presence of macro-
thrombocytes and then as their platelets are too large and
are usually not detected by the particle counter [3].
Finally, the validation of the technique must be carried
out on a large sample of patients; that is why we are unable
to evaluate our hypothesis in our laboratory as GT and BSS
are very rare defects; the number of known patients is not
sufﬁcient to validate this method. In contrast, there are some
other regions such as Iran where 382 patients with GT had
been reported [6].
Conclusion
We can conclude that the proposed technique is simple and
accessible but some problems, cited above, must be solved in
order to validate it. Once done, this method can be set in most
routine haematology laboratories and must be performed each
time a platelet dysfunction is suspected.Overview Box
First Question: What do we already know about the
subject?
Congenital thrombopathies are very rare diseases.
The deﬁnitive diagnosis of these platelet dysfunctions
relies on aggregometric, ﬂow cytometric and molecu-
lar assays. These expensive diagnostic tools are not
always available in routine laboratories, especially
in developing countries, leading to misdiagnosis and
underestimation of the prevalence of these defects.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts
does it have?
The authors suggest a simple and accessible screening
method for detection of congenital thrombopathies
using only a haematology counter and some reagents.
Third question: Among the numerous available studies,
what special further study is proposed for testing the
idea?
The blood of normal subjects should be used for the
standardisation of the method and the deﬁnition of
the normal ranges. Then, it should be validated on
known patients and the results must be compared
to normal controls. Unfortunately, some unsolved
problems, cited in this paper, must be worked out
before the generalisation of the technique.References
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